High Throughput Screening Market

High Throughput Screening Market Size, Share & Trends

The size of global high throughput screening market in terms of revenue was estimated to be worth $28.8 billion in 2024 and is poised to reach $50.2 billion by 2029, growing at a CAGR of 11.8% from 2024 to 2029. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.

There has been a substantial increase in the R&D funding which is supporting the innovation efforts for the development of novel therapeutics. Therefore, increasing drug discovery initiatives are leading to the growing adoption of high throughput screening (HTS) offerings and technologies. However, the high costs associated with the HTS instruments are anticipated to hinder market growth.

High Throughput Screening Market Trends

To know about the assumptions considered for the study, Request for Free Sample Report

Attractive Opportunities in the High Throughput Screening Market

High Throughput Screening Market Dynamics

DRIVER: The growing R&D funding and increasing public and private investments to aid market growth

There have been numerous grants and investments to support academic institutions and research organizations conducting therapeutic drug development research. These grants support drug discovery initiatives. Some instances include- in February 2024, the National Center for Advancing Translational Sciences (NCATS) awarded USD 7.8 million to the University of Pittsburgh School of Medicine (US) for developing a drug discovery system called the Pitt Translational Center for Micro-physiology Systems.

RESTRAINT: High costs associated with HTS instruments

HTS instruments include a wide range of equipment, such as automated liquid handling systems, robotic arms, microplate readers, high-resolution imaging systems, and associated software. The associated costs of these instruments are high. The high initial investment, however, can limit access to high-throughput screening technologies and reduce the rate of their adoption. Some of the instruments, such as flow cytometers and liquid handlers, are expensive. The price of a flow cytometer varies from USD 80,000 to USD 150,000 for sophisticated systems with high throughput. Moreover, liquid handling workstations are also premiumly priced. For instance, the price range falls between USD 100,000 to USD 500,000, depending on its sophistication. This is mainly due to the capital investment required and technological advancements and automation offered in the instruments.

OPPORTUNITY: Increasing adoption of high-throughput screening technologies in emerging markets

The emerging markets include developing economies across the globe. For instance, economies like China and India have observed significant growth in the pharmaceutical and biotechnology industries. Favorable government funding, supported by increasing investments in drug discovery initiatives utilizing HTS technologies, are factors creating increasing opportunities for players in the HTS market. Besides, the growing research applications of high-throughput screening technology in areas such as personalized medicine, genomics, and infectious disease research are supporting its adoption. Governments in emerging economies also prioritize education and training programs in high-throughput screening techniques to build a skilled workforce. Emerging markets create an environment that supports the adoption, development, and application of high-throughput screening technologies with such initiatives. For instance, the Indian government's Department of Biotechnology (DBT) supports the use of HTS technology in various fields, including agriculture and medicine.

CHALLENGE: Complexity in data management, assay development, and analysis

High throughput screening workflow generates large volumes of data from numerous biological or chemical assays. Managing this diverse dataset requires robust data management strategies to ensure accuracy and accessibility. Analyzing HTS data requires advanced statistical methods and bioinformatics tools to identify significant results. This adds to the complexity of data management. In addition, developing assays suitable for HTS involves optimizing conditions for rapid, simultaneous testing of numerous compounds. Ensuring reliability and reproducibility across high-throughput platforms is critical but challenging. Thus, this is a challenge in the growth of this market.

Global High Throughput Screening Market Ecosystem Analysis

The ecosystem for HTS consists of pharmaceutical & biotechnology companies, HTS service providers (screening services), instrument & reagent suppliers, academic & research institutions, technology providers, data management & analysis providers, regulatory authorities (ensuring compliance and safety), and collaborative networks promoting knowledge sharing and collaboration. These stakeholders interact and collaborate to drive the advancement of HTS technologies, enhance drug discovery processes, and develop new therapeutics.

The consumables segment dominated the high throughput screening industry by offerings:

Based on offerings, the high throughput screening market is segmented into consumables, instruments, services, and software. The consumables segment accounted for the largest share of the global high-throughput screening market in 2023. The large share of the segment can be attributed to factors such as the requirement for a wide range of reagents and kits in the HTS workflow, the need for the repeated purchase of consumables, unlike instruments, and a favorable drug discovery research funding/ investment scenario.

The Asia Pacific region is expected to register the fastest growth in the high throughput screening industry during the forecast period.

The Asia Pacific region is expected to account for the fastest-growing region of the high throughput screening market during the forecast period. The Asia Pacific region has a diverse pool of patient population, which adopts a wide range of therapeutics. This drives the need for the development and commercialization of novel therapeutics in the region. Thus, this in turn, supports the growth of the market in the region. Additionally, the region has a strong presence of key global pharmaceutical and biotechnology companies involved in innovation in the pharmaceutical industry.

To know about the assumptions considered for the study, download the pdf brochure

Key players in the high throughput screening market include Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Revvity, Inc. (US), Tecan Group Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), Corning Incorporated (US), Mettler-Toledo International Inc. (US), Lonza (Switzerland), Waters Corporation (US), Sartorius AG (Germany), Eppendorf SE (Germany), Porvair PLC (UK), Greiner AG (Austria), Charles River Laboratories (US), Eurofins Scientific (Europe), Hamilton Company (US), Aurora Biomed Inc. (Canada), Gilson Incorporated (US), Brand GmbH+Co KG (Germany), BMG Labtech GmbH (Germany), DIANA Biotechnologies, A.S. (Czech Republic), Creative Biolabs. (US), HighRes Biosolutions. (US), Biomat Srl (Italy), AXXAM S.p.A. (Italy), Sygnature Discovery Limited (UK), and Crown Bioscience (US).

Scope of the High Throughput Screening Industry:

This report categorizes the high throughput screening market into the following segments and subsegments:

By Offerings

• Consumables
  • Reagents & Assay Kits
  • Laboratory Consumables
• Instruments
  • Liquid Handling Systems
  • Detection Systems
  • Imaging Systems
  • Other Instruments
• Services
• Software

By Technology

• Cell-based Assays
  • 2D Cell Culture
  • 3D Cell Culture
    • Scaffold-based Technology
      • Hydrogels
        • Animal-derived Hydrogels
          • Matrigel
          • Collagen
        • Synthetic Hydrogels
        • Alginate/Agarose
      • Inert Matrix/Solid Scaffolds
      • Micropatterned Surfaces
    • Scaffold-free Technology
      • Ultra-low Binding Plates
      • Hanging-drop Plates
      • Other Scaffold-free Technologies
  • Reporter-based Assays
  • Perfusion Cell Culture
• Lab-on-a-Chip Technology (LOC)
• Label-free Technology

By Application

• Drug Discovery
• Biochemical Screening
• Life Sciences Research
• Other Applications

By End User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations (CROs)
• Other End Users

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia Pacific (APAC)
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific (RoAPAC)
• Latin America
  • Brazil
  • Mexico
  • RoLATAM
• Middle East
  • GCC
    • Saudi Arabia
    • UAE
    • Rest of GCC
• Rest of Middle East
• Africa

Recent Developments of High Throughput Screening Industry

• In October 2023, Revvity Inc. (US), collaborated with SCIEX, a subsidiary of Danaher Corporation (US), to develop mass spectrometry solutions for newborn screening.
• In May 2024, Bio-Rad Laboratories, Inc. (US) launched three new StarBright Red Dyes—StarBright Red 715, 775, and 815—providing greater choice and flexibility in conventional and full-spectrum multicolor flow cytometry panels.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst